S
Silk Technologies
SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications
About Silk Technologies
SilkTech Biopharmaceuticals is a clinical-stage company focused on developing innovative biologic drug products utilizing the natural therapeutic properties of silk-derived proteins. The company's flagship product, SDP 4, is an investigational eye drop designed to treat the signs and symptoms of Dry Eye Disease (DED), a condition affecting up to 340 million people globally, including 45-60 million in the US alone. SDP 4 offers a novel biotherapeutic approach by inhibiting inflammatory mediators and stabilizing the tear film through its unique proteinaceous nature. The formulation is water-based, non-preserved, and stable at room temperature, making it a potentially disruptive solution in the ophthalmic market.
Read full description
SilkTech primarily serves patients suffering from DED, a growing market due to increasing diagnosis rates and awareness. The company's business model revolves around the development and eventual commercialization of its biologic drug products, with revenue generation expected through product sales, partnerships, and licensing agreements once regulatory approvals are obtained.
At a glance
- Founded
- 2013
- Headquarters
- Plymouth, United States
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Silk Technologies.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- SCSkyview Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Silk Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Silk Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.